Sarah Haecker Meeks, PhD

Sarah Haecker Meeks, Ph.D., is a senior executive with extensive experience in the advanced therapies sector, particularly in business development and strategy. She currently holds the position of Business Development & Strategy at Ori Biotech.23

Professional Background

Experience:: Sarah has over 20 years of senior-level management experience in corporate development within the advanced therapies sector.1 Her career includes several notable positions:

• Senior Vice President of Business Development at Ori Biotech (current role)3
• Vice President of Business Development at MaxCyte, Inc.1
• Vice President of Business Development at Synpromics Ltd. (2016-2019)1
• Chief Scientific Officer at Adjuvant Partners (2013-2018)1

Expertise:: Sarah is known for her expertise in:

• Business development
• Strategic planning
• Marketing
• Product commercialization

Education and Early Career

Sarah holds a Doctorate in molecular biology and bioethics from the University of Minnesota and a Bachelor of Science degree in biochemistry from the University of Wisconsin.1 She completed a post-doctoral fellowship with James M. Wilson, MD, Ph.D., at the University of Pennsylvania's Human Gene Therapy Program from 1995 to 2004.1

Notable Achievements

• Part of the founding team of Cardiogen Sciences, Inc. (acquired by Audentes Therapeutics in 2015)1
• Served as Senior Director of Technology Sections at the Alliance for Regenerative Medicine, where she launched and managed the Gene Therapy Section and the Genome Editing Task Force1
• Successfully led business development functions in various companies, utilizing her business acumen and scientific expertise2

Personal Interests

Based in Minneapolis, Sarah enjoys family time, gardening, running, and hockey. Since 2017, she has served on the Board of the Minneapolis United Soccer Club, leading fundraising efforts and directing its Advancement Committee.1